Paul Hastings, Nkarta CEO
With no upfront payment or milestones on the line, Nkarta and CRISPR join forces on CAR-NK search
Most deals in biotech come with hefty upfront payments attached, and the promise of big biobucks if a program works out. Not this one. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
